Pharmaceuticals and Onyx
Pharmaceuticals announced that the FDA has approved a supplemental New Drug
Application for Nexavar (sorafenib) tablets for the treatment of patients with
unresectable hepatocellular carcinoma, or liver cancer. Nexavar, an oral
anticancer drug, is the first approved systemic therapy for liver cancer and
the only one shown to significantly improve overall survival in patients with
that the FDA has approved Protonix
(pantoprazole sodium) delayed-release oral suspension, providing adult patients
who cannot swallow tablets with an effective and convenient way to treat their
erosive gastroesophageal reflux disease.
AstraZeneca said the
FDA has approved once-daily Seroquel XR
(quetiapine fumarate) extended-release tablets for maintenance treatment of
schizophrenia in adult patients.